Showing results for:
Deferasirox is FDA approved to remove excess iron that is in the body because of blood transfusions. Deferasirox works by attaching to iron molecules in the body so they can be excreted (removed from the body) in feces.Deferasirox is indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. This indication is approved under accelerated approval based on a reduction of liver iron concentrations and serum ferritin levels. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Exjade® Jadenu® Deferasirox
Pirtobrutinib is indicated for the treatment ofAdult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Pirtobrutinib Jaypirca®
Ruxolitinib is FDA approved for treatment of Intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adultsPolycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyureaSteroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and olderChronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Jakafi® Ruxolitinib